Market concentration of new antibiotic sales

We calculate the average sales of new antibiotics during their first 8 years on the market. The discounted net present value is only $240 m in total per antibiotic, well below costs of supplying these products. The reliance on the US for sales is striking: the US market accounts for 84% of sales during the first 8 years. These facts clarify the need for additional revenues, especially from other countries, to support incentives for the development of new antibiotics. Market entry rewards may be of particular value.

Automated summary

The average sales of new antibiotics during their first 8 years on the market are inadequate to cover costs of supplying the products, with a striking reliance on the US market accounting for 84% of sales. Additional revenues, especially from other countries, are needed to support incentives for the development of new antibiotics, with market entry rewards potentially being of particular value.